Gan & Lee Pharmaceuticals. (SHA:603087)
China
· Delayed Price · Currency is CNY 44.77
-1.56 (-3.37%)
Feb 28, 2025, 2:44 PM CST
SHA:603087 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Feb '25 Feb 27, 2025 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Market Capitalization | 26,708 | 31,066 | 18,429 | 39,499 | 74,247 | - | Upgrade
|
| Market Cap Growth | 14.98% | 68.57% | -53.34% | -46.80% | - | - | Upgrade
|
| Enterprise Value | 21,645 | 26,918 | 13,463 | 34,935 | 70,382 | - | Upgrade
|
| Last Close Price | 44.73 | 51.86 | 32.09 | 68.84 | 128.99 | - | Upgrade
|
| PE Ratio | 45.37 | 91.35 | - | 27.19 | 60.33 | - | Upgrade
|
| Forward PE | 30.43 | 11.40 | 11.40 | 25.81 | 50.01 | - | Upgrade
|
| PS Ratio | 8.94 | 11.91 | 10.76 | 10.94 | 22.08 | - | Upgrade
|
| PB Ratio | 2.47 | 2.89 | 1.92 | 3.88 | 8.31 | - | Upgrade
|
| P/TBV Ratio | 2.66 | 2.97 | 1.98 | 4.00 | 8.53 | - | Upgrade
|
| P/FCF Ratio | 177.18 | - | - | 102.30 | 112.63 | - | Upgrade
|
| P/OCF Ratio | 44.70 | 283.83 | 62.12 | 36.63 | 59.81 | - | Upgrade
|
| EV/Sales Ratio | 7.34 | 10.32 | 7.86 | 9.67 | 20.94 | - | Upgrade
|
| EV/EBITDA Ratio | 44.84 | 68.22 | - | 22.24 | 44.70 | - | Upgrade
|
| EV/EBIT Ratio | 86.70 | 149.52 | - | 25.13 | 49.75 | - | Upgrade
|
| EV/FCF Ratio | 143.59 | - | - | 90.48 | 106.77 | - | Upgrade
|
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.00 | - | - | Upgrade
|
| Debt / EBITDA Ratio | 0.01 | 0.02 | - | 0.01 | - | - | Upgrade
|
| Debt / FCF Ratio | 0.02 | - | - | 0.04 | - | - | Upgrade
|
| Asset Turnover | 0.26 | 0.23 | 0.16 | 0.35 | 0.43 | 0.54 | Upgrade
|
| Inventory Turnover | 0.84 | 0.96 | 0.68 | 0.70 | 0.64 | 0.55 | Upgrade
|
| Quick Ratio | 6.62 | 6.77 | 6.05 | 12.65 | 13.14 | 5.66 | Upgrade
|
| Current Ratio | 8.04 | 7.98 | 6.97 | 14.15 | 14.54 | 6.79 | Upgrade
|
| Return on Equity (ROE) | 5.51% | 3.35% | -4.45% | 15.21% | 17.08% | 23.97% | Upgrade
|
| Return on Assets (ROA) | 1.35% | 1.01% | -3.94% | 8.54% | 11.38% | 15.50% | Upgrade
|
| Return on Capital (ROIC) | 1.48% | 1.11% | -4.27% | 9.09% | 12.27% | 17.05% | Upgrade
|
| Return on Capital Employed (ROCE) | 2.19% | 1.65% | - | 13.41% | 15.55% | 23.87% | Upgrade
|
| Earnings Yield | 2.17% | 1.09% | -2.38% | 3.68% | 1.66% | - | Upgrade
|
| FCF Yield | 0.56% | -1.43% | -3.73% | 0.98% | 0.89% | - | Upgrade
|
| Dividend Yield | 1.12% | 0.39% | - | 0.44% | 0.31% | - | Upgrade
|
| Payout Ratio | 20.36% | - | - | 15.46% | 16.30% | - | Upgrade
|
| Buyback Yield / Dilution | -3.48% | -0.59% | -0.46% | -5.28% | -5.43% | -0.09% | Upgrade
|
| Total Shareholder Return | -2.37% | -0.20% | -0.46% | -4.84% | -5.12% | -0.09% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.